Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on IVIG (Feb 2018)

Posted by Matt Breese on Feb 9, 2018

Find me on:

According to our recent payer coverage analysis for immune globulin treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access breakdown across pharmacy and medical benefits reveals a fragmented and complex landscape. We see a severe increase in restrictions for medicare pharmacy benefit formularies but a slight relaxation in restrictions for medicare medical benefit coverage.

mmit-reality-check-ivig 1q2018.png

Source: MMIT data as of Q1 2018

Trends:  We see some significant trends within the specialty pharmaceutical industry and IVIG specifically. Events like the extension of the Medicare demo for IVIG treatments and expectations around M&A activity should make their mark on the treatment landscape in 2018

To read the full Reality Check on immune globulin treatments with key findings on clinical characteristics, IVIG drug market access and payer coverage, please click on the button below: 

MMIT-RC_Thumbnail_1-1.pngView Reality Check

Topics: Specialty, Market Access, Branding & Marketing